L type glui

Blood samples were collected from all participants in tubes without anticoagulants on the same day as the ultrasound examination during the early follicular phase. Serum FSH levels were measured using an Elecsys FSH assay (Roche Diagnostics Corp., Indianapolis, IN, USA) and serum LH levels were measured using an Elecsys LH assay (Roche Diagnostics Corp.). Insulin levels were measured using an Elecsys Insulin assay (Roche Diagnostics Corp.), and fasting glucose levels and levels during a standard 2-hour 75-gram oral glucose tolerance test were measured using L-Type GluI (Wako Pure Chemical Industries, Osaka, Japan). The total cholesterol and triglyceride levels were measured using a Pureauto S (Sekisui Medical, Tokyo, Japan), and high density lipoprotein and low density lipoprotein were measured using a Cholestest (Sekisui Medical, Tokyo, Japan). Both the intraassay and interassay coefficients of variation for all measurements were less than 5%.

Blood samples were taken from all study participants following overnight fasting in accordance with the guidelines of the Declaration of Helsinki, and sera were obtained by centrifugation to evaluate biochemical parameters. Fasting glucose levels and levels at 2 hours after 75-g glucose ingestion during a 2-hour OGTT were measured using L-Type GluI (Wako Pure Chemical Industries, Osaka, Japan). Fasting insulin levels were evaluated using an Elecsys Insulin assay (Roche Diagnostics Corp., Basel, Switzerland). The intra- and inter-assay coefficients of variation were <5% for all measurements.
Fasting-state homeostatic ISAIs derived from a combination of fasting glucose and insulin levels were calculated according to the following formulas:
HOMA-IR=glucose (mg/dL)×insulin (μU/mL)/405,
GIR=glucose (mg/dL)/insulin (μU/mL); and,
QUICKI=1/{log [insulin (μU/mL)]+log [glucose (mg/dL)]}.
Abnormal glucose tolerance, which comprises IGT and diabetes [17 (link),18 (link)] was defined using the criterion established by the American Diabetes Association (ADA) [19 (link)]: a 2-hour postload glucose (2-hr PG) concentration ≥140 mg/dL after an OGTT.